TAGLN2 overexpression activated the PI3K/Akt/GST-3β pathway and downregulated the expression of PTEN, which promoted paclitaxel treatment resistance and the migration and invasion of breast cancer cells [18]. This evidence concerns the gene AKT1 and breast carcinoma.